Regulatory press release

BBS-Bioactive Bone Substitutes Plc: Production Director Kimmo Tyni resigns from the Company

BBS-Bioactive Bone Substitutes Plc | Company Release | November 29, 2024 at 15:00:00 EET

BBS-Bioactive Bone Substitutes Plc: Production Director Kimmo Tyni resigns from the Company

Production Director and the member of management team Kimmo Tyni has decided to resign from BBS and move to a new position outside the Company. Tyni will continue in his position until December 31, 2024.

Production Director Kimmo Tyni: "I am grateful for the opportunity to be part of this journey and to collaborate with a talented team. I am eagerly looking forward to new challenges and wish the Company and all its skilled employees success in the future as well."

CEO Juliusz Rakowski: "I thank Kimmo for his contribution in preparing the Reisjärvi Production Site for the commercial phase. We wish him all the best in his future challenges."

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi